First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
Abstract Lung carcinosarcoma is acknowledged as a rare form of lung cancer. Due to its rarity, the inability to conduct large‐scale clinical trials and interventions is currently carried out based on empirical evidence. In this study, we report the case of a 73‐year‐old female patient diagnosed with...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15134 |
| _version_ | 1797405572786552832 |
|---|---|
| author | Naoya Ishibashi Toshiharu Tabata Ryo Nonomura Yutaka Oshima Takanobu Sasaki Hideki Mitomo Takafumi Sugawara Motoyasu Sagawa |
| author_facet | Naoya Ishibashi Toshiharu Tabata Ryo Nonomura Yutaka Oshima Takanobu Sasaki Hideki Mitomo Takafumi Sugawara Motoyasu Sagawa |
| author_sort | Naoya Ishibashi |
| collection | DOAJ |
| description | Abstract Lung carcinosarcoma is acknowledged as a rare form of lung cancer. Due to its rarity, the inability to conduct large‐scale clinical trials and interventions is currently carried out based on empirical evidence. In this study, we report the case of a 73‐year‐old female patient diagnosed with postoperative recurrence of lung carcinosarcoma. The resected tumor was diagnosed as lung carcinosarcoma, and genetic testing revealed the presence of the epidermal growth factor receptor (EGFR) exon21 L858R. Approximately 2 years postoperatively, the tumor recurred and the patient was treated with erlotinib plus ramucirumab, which were effective in controlling metastatic disease. Erlotinib plus ramucirumab is therefore a treatment option for EGFR mutation‐positive lung carcinosarcoma. |
| first_indexed | 2024-03-09T03:11:57Z |
| format | Article |
| id | doaj.art-72def1835b254b798045913ba7ba8812 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-09T03:11:57Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-72def1835b254b798045913ba7ba88122023-12-03T23:59:35ZengWileyThoracic Cancer1759-77061759-77142023-12-0114343415341810.1111/1759-7714.15134First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutationNaoya Ishibashi0Toshiharu Tabata1Ryo Nonomura2Yutaka Oshima3Takanobu Sasaki4Hideki Mitomo5Takafumi Sugawara6Motoyasu Sagawa7Department of Thoracic Surgery Tohoku Medical and Pharmaceutical University Hospital Sendai City JapanDepartment of Thoracic Surgery Tohoku Medical and Pharmaceutical University Hospital Sendai City JapanDepartment of Thoracic Surgery Tohoku Medical and Pharmaceutical University Hospital Sendai City JapanDepartment of Thoracic Surgery Tohoku Medical and Pharmaceutical University Hospital Sendai City JapanDepartment of Thoracic Surgery Tohoku Medical and Pharmaceutical University Hospital Sendai City JapanDepartment of Thoracic Surgery Tohoku Medical and Pharmaceutical University Hospital Sendai City JapanDepartment of Thoracic Surgery Tohoku Medical and Pharmaceutical University Hospital Sendai City JapanDepartment of Thoracic Surgery Tohoku Medical and Pharmaceutical University Hospital Sendai City JapanAbstract Lung carcinosarcoma is acknowledged as a rare form of lung cancer. Due to its rarity, the inability to conduct large‐scale clinical trials and interventions is currently carried out based on empirical evidence. In this study, we report the case of a 73‐year‐old female patient diagnosed with postoperative recurrence of lung carcinosarcoma. The resected tumor was diagnosed as lung carcinosarcoma, and genetic testing revealed the presence of the epidermal growth factor receptor (EGFR) exon21 L858R. Approximately 2 years postoperatively, the tumor recurred and the patient was treated with erlotinib plus ramucirumab, which were effective in controlling metastatic disease. Erlotinib plus ramucirumab is therefore a treatment option for EGFR mutation‐positive lung carcinosarcoma.https://doi.org/10.1111/1759-7714.15134EGFR L858Rerlotiniblung carcinosarcomanon‐small cell lung cancerramucirumab |
| spellingShingle | Naoya Ishibashi Toshiharu Tabata Ryo Nonomura Yutaka Oshima Takanobu Sasaki Hideki Mitomo Takafumi Sugawara Motoyasu Sagawa First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation Thoracic Cancer EGFR L858R erlotinib lung carcinosarcoma non‐small cell lung cancer ramucirumab |
| title | First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation |
| title_full | First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation |
| title_fullStr | First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation |
| title_full_unstemmed | First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation |
| title_short | First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation |
| title_sort | first case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with egfr l858r mutation |
| topic | EGFR L858R erlotinib lung carcinosarcoma non‐small cell lung cancer ramucirumab |
| url | https://doi.org/10.1111/1759-7714.15134 |
| work_keys_str_mv | AT naoyaishibashi firstcasereportoferlotinibplusramucirumabtreatmentforlungcarcinosarcomawithegfrl858rmutation AT toshiharutabata firstcasereportoferlotinibplusramucirumabtreatmentforlungcarcinosarcomawithegfrl858rmutation AT ryononomura firstcasereportoferlotinibplusramucirumabtreatmentforlungcarcinosarcomawithegfrl858rmutation AT yutakaoshima firstcasereportoferlotinibplusramucirumabtreatmentforlungcarcinosarcomawithegfrl858rmutation AT takanobusasaki firstcasereportoferlotinibplusramucirumabtreatmentforlungcarcinosarcomawithegfrl858rmutation AT hidekimitomo firstcasereportoferlotinibplusramucirumabtreatmentforlungcarcinosarcomawithegfrl858rmutation AT takafumisugawara firstcasereportoferlotinibplusramucirumabtreatmentforlungcarcinosarcomawithegfrl858rmutation AT motoyasusagawa firstcasereportoferlotinibplusramucirumabtreatmentforlungcarcinosarcomawithegfrl858rmutation |